Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 12;2012(9):CD001895.
doi: 10.1002/14651858.CD001895.pub3.

Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation

Martha Hickey  1 , Jenny M Higham, Ian Fraser
Affiliations

Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation

Martha Hickey et al. Cochrane Database Syst Rev. .

Abstract

Background: Irregular menstrual bleeding may arise due to exogenous sex steroids, lesions of the genital tract or be associated with anovulation. Irregular bleeding due to oligo/anovulation (previously called dysfunctional uterine bleeding or DUB) is more common at the extremes of reproductive life, and in women with ovulatory disorders such as polycystic ovary syndrome (PCOS). In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy. This is the rationale for using cyclical progestogens during the second half of the menstrual cycle, in order to provoke a regular withdrawal bleed. Continuous progestogen is intended to induce endometrial atrophy and hence to prevent oestrogen-stimulated endometrial proliferation. Progestogens, and oestrogens and progestogens in combination, are widely used in the management of irregular menstrual bleeding, but the regime, dose and type of progestogen used vary widely, with little consensus about the optimum treatment approach.

Objectives: To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.

Search methods: We searched the following databases in February 2012: Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and reference lists of articles.

Selection criteria: All randomised controlled trials of progestogens (via any route) alone or in combination with oestrogens in the treatment of irregular menstrual bleeding associated with oligo/anovulation.

Data collection and analysis: Study quality assessment and data extraction were carried out independently by two review authors. All authors were experts in the content of this review.

Main results: No randomised trials were identified that compared progestogens with oestrogens and progestogens or with placebo in the management of irregular bleeding associated with oligo/anovulation.

Authors' conclusions: There is a paucity of randomised studies relating to the use of progestogens and of oestrogens and progestogens in combination in the treatment of irregular menstrual bleeding associated with anovulation. There is no consensus about which regimens are most effective. Further research is needed to establish the role of these hormonal treatments in the management of this common gynaecological problem.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

References

References to studies excluded from this review

Aksu 1997 {published data only}
    1. Aksu MF, Madazli R, Budak E, Cepni I, Benian A. High‐dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Australian & New Zealand Journal of Obstetrics & Gynaecology 1997;37(2):228‐31. - PubMed
Bishop 1960 {published data only}
    1. Bishop PMF. Treatment of functional menstrual disorders with norethisterone. British Medical Journal 1960;9:1103‐5. - PMC - PubMed
Falcone 1994 {published data only}
    1. Falcone T, Desjardins C, Bourque J, Granger L, Hemmings R, Quiros E. Dysfunctional uterine bleeding in adolescents. Journal of Reproductive Medicine 1994;39(10):761‐4. - PubMed
Fraser 1990 {published and unpublished data}
    1. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Australian & New Zealand Journal of Obstetrics & Gynaecology 1990;30:353‐6. - PubMed
Munro 2006 {published data only}
    1. Munro M, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding. Obstetrics and Gynecology 2006;108(4):924‐9. - PubMed
Saarikoski 1990 {published data only}
    1. Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre‐menopausal bleeding disorders. Maturitas 1990;12:89‐97. - PubMed
Wollter 1997 {published data only}
    1. Wollter‐Svensson LO, Stadberg E, Andersson K, Mattsson L‐A, Odlind V, Persson I. Intrauterine administration of levonorgestrel 5 and 10 mcg/24 hours in perimenopausal hormone replacement therapy. Acta Obstetricia Gynecologica Scandinavica 1997;76:449‐54. - PubMed

Additional references

Azziz 2004
    1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89(6):2745‐9. - PubMed
Gellersen 2007
    1. Gellersen B, Brosens IA, Brosens JJ. Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives. Seminars in Reproductive Medicine 2007;25(6):445‐53. - PubMed
Hale 2009
    1. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Pract Res Clin Obstet Gynaecol 2009;23(1):7‐23. - PubMed
Hale 2011
    1. Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle‐ and late‐reproductive age and the menopausal transition. Obstet Gynecol 2011;115(2 Pt 1):249‐56. - PubMed
Harlow 2012
    1. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Reba RW, Sherman S, Sluss PM, de Villiers TJ for the STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19(4):387‐95. - PMC - PubMed
Hickey 2008
    1. Hickey M, Salamonsen LA. Endometrial structural and inflammatory changes with exogenous progestogens.. Trends in Endocrinology and Metabolism 2008;19(5):167‐74. - PubMed
Lacey 2009
    1. Lacey JVJ, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63(1):39‐44. - PubMed
Munro 2011
    1. Munro MG, Critchley HO, Fraser IS. The flexible FIGO classification concept for underlying causes of abnormal uterine bleeding. Seminars in Reproductive Medicine 2011;29(5):391‐9. - PubMed
van Hooff 2004
    1. Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive values of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at aged 15 years for oligo‐amenorrhoea at aged 18 years. Human Reproduction 2004;19(2):383‐92. - PubMed

Publication types